{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:10:27Z","timestamp":1768533027440,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s11096-020-01018-z","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T04:02:28Z","timestamp":1586318548000},"page":"721-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Aromatase inhibitors associated osteonecrosis of jaw: signal refining to identify pseudo safety signals"],"prefix":"10.1007","volume":"42","author":[{"given":"Reddy","family":"Neha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Beulah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bellapu","family":"Anusha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharma","family":"Vasista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chacko","family":"Stephy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viswam","family":"Subeesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,8]]},"reference":[{"key":"1018_CR1","first-page":"149","volume-title":"Spontaneous reporting in the United States","author":"DL Kennedy","year":"2000","unstructured":"Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. Pharmacoepidemiology, 3 ed. England: Wiley; 2000. p. 149\u201374.","edition":"Pharmacoepidemi"},{"issue":"2","key":"1018_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40264-012-0014-6","volume":"36","author":"SN Pal","year":"2013","unstructured":"Pal SN, Duncombe C, Falzon D, Olsson S. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75\u201381.","journal-title":"Drug Saf"},{"key":"1018_CR3","volume-title":"Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action","author":"WH Organization","year":"2002","unstructured":"Organization WH. Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action. Geneva: World Health Organization; 2002."},{"issue":"6","key":"1018_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002018-199716060-00002","volume":"16","author":"RH Meyboom","year":"1997","unstructured":"Meyboom RH, Egberts AC, Edwards IR, Hekster YA, de Koning FH, Gribnau FW. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16(6):355\u201365.","journal-title":"Drug Saf"},{"issue":"8","key":"1018_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00228-008-0475-9","volume":"64","author":"L H\u00e4rmark","year":"2008","unstructured":"H\u00e4rmark L, Van Grootheest A. Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol. 2008;64(8):743\u201352.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"1018_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist M, St\u00e5hl M, Bate A, Edwards IR, Meyboom RH. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 2000;23(6):533\u201342.","journal-title":"Drug Saf"},{"issue":"2","key":"1018_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","volume":"57","author":"AM Wilson","year":"2004","unstructured":"Wilson AM, Thabane L, Holbrook A. Application of data mining techniques in pharmacovigilance. Br J Clin Pharmacol. 2004;57(2):127\u201334.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1018_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00002018-200326030-00003","volume":"26","author":"M Hauben","year":"2003","unstructured":"Hauben M, Zhou X. Quantitative methods in pharmacovigilance. Drug Saf. 2003;26(3):159\u201386.","journal-title":"Drug Saf"},{"issue":"11","key":"1018_CR9","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/00002018-200528110-00002","volume":"28","author":"J Almenoff","year":"2005","unstructured":"Almenoff J, Tonning JM, Gould AL, Szarfman A, Hauben M, Ouellet-Hellstrom R, et al. Perspectives on the use of data mining in pharmacovigilance. Drug Saf. 2005;28(11):981\u20131007.","journal-title":"Drug Saf"},{"issue":"1","key":"1018_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1541-0420.2009.01262.x","volume":"66","author":"I Ahmed","year":"2010","unstructured":"Ahmed I, Dalmasso C, Haramburu F, Thiessard F, Bro\u00ebt P, Tubert-Bitter P. False discovery rate estimation for frequentist pharmacovigilance signal detection methods. Biometrics. 2010;66(1):301\u20139.","journal-title":"Biometrics"},{"key":"1018_CR11","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard FDA. https:\/\/www.fda.gov\/drugs\/guidancecomplianceregulatoryinformation\/surveillance\/adversedrugeffects\/ucm070093.htm. Accessed 27 July 2019."},{"issue":"6","key":"1018_CR12","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","volume":"11","author":"R B\u00f6hm","year":"2016","unstructured":"B\u00f6hm R, von Hehn L, Herdegen T, Klein H-J, Bruhn O, Petri H, et al. OpenVigil FDA\u2014inspection of US American adverse drug events pharmacovigilance data and novel clinical applications. PLoS ONE. 2016;11(6):e0157753.","journal-title":"PLoS ONE"},{"key":"1018_CR13","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C, De Ponti F (2012) Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA adverse event reporting system (AERS). In: Data mining applications in engineering and medicine, inTech.","DOI":"10.5772\/50095"},{"key":"1018_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ajp.2017.09.005","volume":"30","author":"V Subeesh","year":"2017","unstructured":"Subeesh V, Singh H, Maheswari E, Beulah E. Novel adverse events of vortioxetine: a disproportionality analysis in USFDA adverse event reporting system database. Asian Journal of Psychiatry. 2017;30:152\u20136.","journal-title":"Asian Journal of Psychiatry"},{"key":"1018_CR15","unstructured":"FDAble http:\/\/www.fdable.com\/basic_query\/aers_analysis. Accessed 4 Aug 2019."},{"issue":"7","key":"1018_CR16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1038\/nbt0709-601","volume":"27","author":"LA Pratt","year":"2009","unstructured":"Pratt LA, Danese PN. More eyeballs on AERS. Nat Biotechnol. 2009;27(7):601.","journal-title":"Nat Biotechnol"},{"issue":"8","key":"1018_CR17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/pds.3561","volume":"23","author":"I Grigoriev","year":"2014","unstructured":"Grigoriev I, zu Castell W, Tsvetkov P, Antonov AV. AERS spider: an online interactive tool to mine statistical associations in adverse event reporting system. Pharmacoepidemiol Drug Saf. 2014;23(8):795\u2013801.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1018_CR18","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1517\/14740338.4.5.929","volume":"4","author":"M Hauben","year":"2005","unstructured":"Hauben M, Madigan D, Gerrits CM, Walsh L, Van Puijenbroek EP. The role of data mining in pharmacovigilance. Exp Opin Drug Saf. 2005;4(5):929\u201348.","journal-title":"Exp Opin Drug Saf"},{"issue":"5","key":"1018_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ctrv.2015.04.007","volume":"41","author":"IS Hamadeh","year":"2015","unstructured":"Hamadeh IS, Ngwa BA, Gong Y. Drug induced osteonecrosis of the jaw. Cancer Treat Rev. 2015;41(5):455\u201364.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1018_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.4103\/0975-5950.127643","volume":"4","author":"S Gupta","year":"2013","unstructured":"Gupta S, Gupta H, Mandhyan D, Srivastava S. Bisphophonates related osteonecrosis of the jaw. Natl J Maxillofac Surg. 2013;4(2):151.","journal-title":"Natl J Maxillofac Surg"},{"issue":"10","key":"1018_CR21","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg. 2014;72(10):1938\u201356.","journal-title":"J Oral Maxillofac Surg"},{"issue":"2","key":"1018_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.oooo.2018.09.008","volume":"127","author":"O Nicolatou-Galitis","year":"2019","unstructured":"Nicolatou-Galitis O, Schi\u00f8dt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;127(2):117\u201335.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-020-01018-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-020-01018-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T16:49:54Z","timestamp":1722703794000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-020-01018-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1018"],"URL":"https:\/\/doi.org\/10.1007\/s11096-020-01018-z","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"28 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}